![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LUM |
Gene summary for LUM |
![]() |
Gene information | Species | Human | Gene symbol | LUM | Gene ID | 4060 |
Gene name | lumican | |
Gene Alias | LDC | |
Cytomap | 12q21.33 | |
Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | P51884 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4060 | LUM | AEH-subject1 | Human | Endometrium | AEH | 2.21e-32 | -1.03e+00 | -0.3059 |
4060 | LUM | AEH-subject2 | Human | Endometrium | AEH | 1.32e-45 | -1.25e+00 | -0.2525 |
4060 | LUM | AEH-subject3 | Human | Endometrium | AEH | 2.86e-47 | -1.19e+00 | -0.2576 |
4060 | LUM | AEH-subject4 | Human | Endometrium | AEH | 4.01e-12 | -7.54e-01 | -0.2657 |
4060 | LUM | AEH-subject5 | Human | Endometrium | AEH | 1.78e-60 | -1.32e+00 | -0.2953 |
4060 | LUM | EEC-subject1 | Human | Endometrium | EEC | 1.86e-51 | -1.29e+00 | -0.2682 |
4060 | LUM | EEC-subject2 | Human | Endometrium | EEC | 2.05e-62 | -1.32e+00 | -0.2607 |
4060 | LUM | EEC-subject3 | Human | Endometrium | EEC | 9.52e-57 | -1.25e+00 | -0.2525 |
4060 | LUM | EEC-subject4 | Human | Endometrium | EEC | 2.62e-35 | -1.09e+00 | -0.2571 |
4060 | LUM | EEC-subject5 | Human | Endometrium | EEC | 1.83e-55 | -1.25e+00 | -0.249 |
4060 | LUM | GSM5276934 | Human | Endometrium | EEC | 3.34e-08 | -5.59e-01 | -0.0913 |
4060 | LUM | GSM5276935 | Human | Endometrium | EEC | 1.22e-58 | -1.32e+00 | -0.123 |
4060 | LUM | GSM5276937 | Human | Endometrium | EEC | 4.24e-07 | -4.63e-01 | -0.0897 |
4060 | LUM | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.58e-48 | -1.34e+00 | -0.1869 |
4060 | LUM | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 1.81e-48 | -1.38e+00 | -0.1875 |
4060 | LUM | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 2.37e-55 | -1.38e+00 | -0.1883 |
4060 | LUM | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.35e-63 | -1.33e+00 | -0.1934 |
4060 | LUM | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.09e-74 | -1.38e+00 | -0.1917 |
4060 | LUM | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 1.70e-69 | -1.38e+00 | -0.1916 |
4060 | LUM | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 1.27e-02 | -4.64e-01 | -0.1269 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00716047 | Skin | AK | transforming growth factor beta production | 12/1910 | 43/18723 | 9.25e-04 | 7.53e-03 | 12 |
GO:000181917 | Skin | AK | positive regulation of cytokine production | 67/1910 | 467/18723 | 2.59e-03 | 1.67e-02 | 67 |
GO:00614483 | Skin | AK | connective tissue development | 40/1910 | 252/18723 | 3.17e-03 | 1.95e-02 | 40 |
GO:00512162 | Skin | AK | cartilage development | 31/1910 | 190/18723 | 5.79e-03 | 3.14e-02 | 31 |
GO:00301985 | Skin | SCCIS | extracellular matrix organization | 32/919 | 301/18723 | 3.46e-05 | 9.17e-04 | 32 |
GO:00430625 | Skin | SCCIS | extracellular structure organization | 32/919 | 302/18723 | 3.69e-05 | 9.65e-04 | 32 |
GO:00452295 | Skin | SCCIS | external encapsulating structure organization | 32/919 | 304/18723 | 4.20e-05 | 1.06e-03 | 32 |
GO:00301994 | Skin | SCCIS | collagen fibril organization | 11/919 | 61/18723 | 1.65e-04 | 3.30e-03 | 11 |
GO:000181918 | Skin | SCCIS | positive regulation of cytokine production | 38/919 | 467/18723 | 1.63e-03 | 1.81e-02 | 38 |
GO:007163414 | Skin | SCCIS | regulation of transforming growth factor beta production | 7/919 | 41/18723 | 3.49e-03 | 3.11e-02 | 7 |
GO:007160414 | Skin | SCCIS | transforming growth factor beta production | 7/919 | 43/18723 | 4.60e-03 | 3.82e-02 | 7 |
GO:005121611 | Skin | SCCIS | cartilage development | 18/919 | 190/18723 | 5.86e-03 | 4.52e-02 | 18 |
GO:006144811 | Skin | SCCIS | connective tissue development | 22/919 | 252/18723 | 6.57e-03 | 4.89e-02 | 22 |
GO:003019812 | Thyroid | ATC | extracellular matrix organization | 152/6293 | 301/18723 | 8.63e-10 | 2.24e-08 | 152 |
GO:004306212 | Thyroid | ATC | extracellular structure organization | 152/6293 | 302/18723 | 1.17e-09 | 2.94e-08 | 152 |
GO:004522912 | Thyroid | ATC | external encapsulating structure organization | 152/6293 | 304/18723 | 2.11e-09 | 5.08e-08 | 152 |
GO:003019911 | Thyroid | ATC | collagen fibril organization | 43/6293 | 61/18723 | 4.24e-09 | 9.57e-08 | 43 |
GO:00614484 | Thyroid | ATC | connective tissue development | 112/6293 | 252/18723 | 2.08e-04 | 1.38e-03 | 112 |
GO:007160422 | Thyroid | ATC | transforming growth factor beta production | 25/6293 | 43/18723 | 8.24e-04 | 4.53e-03 | 25 |
GO:007163422 | Thyroid | ATC | regulation of transforming growth factor beta production | 24/6293 | 41/18723 | 9.12e-04 | 4.92e-03 | 24 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0520527 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
hsa0520536 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
hsa0520543 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa0520553 | Oral cavity | EOLP | Proteoglycans in cancer | 53/1218 | 205/8465 | 9.07e-06 | 5.33e-05 | 3.14e-05 | 53 |
hsa0520562 | Oral cavity | NEOLP | Proteoglycans in cancer | 56/1112 | 205/8465 | 3.49e-08 | 5.85e-07 | 3.68e-07 | 56 |
hsa0520572 | Oral cavity | NEOLP | Proteoglycans in cancer | 56/1112 | 205/8465 | 3.49e-08 | 5.85e-07 | 3.68e-07 | 56 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LUM | SNV | Missense_Mutation | c.704N>A | p.Arg235His | p.R235H | P51884 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-BH-A18R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LUM | SNV | Missense_Mutation | rs267603717 | c.718G>A | p.Glu240Lys | p.E240K | P51884 | protein_coding | tolerated(1) | benign(0.003) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
LUM | SNV | Missense_Mutation | c.397G>C | p.Gly133Arg | p.G133R | P51884 | protein_coding | tolerated(0.37) | benign(0.258) | TCGA-EW-A1OX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
LUM | SNV | Missense_Mutation | c.118N>A | p.Glu40Lys | p.E40K | P51884 | protein_coding | deleterious(0.03) | probably_damaging(0.949) | TCGA-LP-A5U2-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
LUM | SNV | Missense_Mutation | novel | c.952N>A | p.Glu318Lys | p.E318K | P51884 | protein_coding | tolerated(0.16) | benign(0) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
LUM | deletion | Frame_Shift_Del | novel | c.324delA | p.Arg110GlufsTer6 | p.R110Efs*6 | P51884 | protein_coding | TCGA-EK-A2RK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | ||
LUM | SNV | Missense_Mutation | rs267603717 | c.718N>A | p.Glu240Lys | p.E240K | P51884 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
LUM | SNV | Missense_Mutation | novel | c.784T>C | p.Ser262Pro | p.S262P | P51884 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
LUM | SNV | Missense_Mutation | c.989N>A | p.Arg330His | p.R330H | P51884 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD | |
LUM | SNV | Missense_Mutation | c.511N>A | p.Leu171Met | p.L171M | P51884 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4060 | LUM | DRUGGABLE GENOME | FAS LIGAND | 15051477 |
Page: 1 |